Citius Pharmaceuticals, Inc. (CTXR) Financial Statements (2024 and earlier)

Company Profile

Business Address 11 COMMERCE DRIVE
CRANFORD, NJ 07016
State of Incorp. NV
Fiscal Year End September 30
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
12/31/2022
MRQ
9/30/2022
9/30/2021
9/30/2020
9/30/2019
9/30/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments36,88741,71270,07313,8607,8949,184
Cash and cash equivalents36,88741,71270,07313,8607,8949,184
Receivables      818
Prepaid expense5,4302,8532,7411224858
Total current assets:42,31744,56472,81413,9827,94210,060
Noncurrent Assets
Operating lease, right-of-use asset6006468239861,138
Property, plant and equipment347211
Intangible assets, net (including goodwill)9,3479,3479,3479,3471,5871,587
Goodwill9,3479,3479,3479,3471,5871,587
Other undisclosed noncurrent assets59,43859,43859,43819,45718,31919,402
Total noncurrent assets:69,38869,43569,61529,79221,04420,990
TOTAL ASSETS:111,705113,999142,42943,77428,98631,051
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities4,3354,3333,8053,7654,4353,012
Interest and dividends payable 907458
Employee-related liabilities2,1071,7621,9061,6551,4011,199
Accounts payable1,5381,1651,2771,8562,7141,573
Accrued liabilities6901,405622164246182
Debt    173173173
Other undisclosed current liabilities202197177159  
Total current liabilities:4,5374,5303,9824,0974,6083,185
Noncurrent Liabilities
Long-term debt and lease obligation  4816781,020  
Long-term debt, excluding current maturities    165  
Liabilities, other than long-term debt6,1345,5624,9864,986  
Deferred income tax liabilities5,7065,5624,9864,986 
Operating lease, liability429481678855 
Total noncurrent liabilities:6,1346,0435,6646,006  
Total liabilities:10,67210,5739,64610,1034,6083,185
Equity
Equity, attributable to parent100,433102,826132,18233,67124,37927,866
Common stock146146146562916
Additional paid in capital233,569232,368228,084104,20980,17068,107
Accumulated deficit(133,282)(129,688)(96,048)(70,594)(55,820)(40,258)
Equity, attributable to noncontrolling interest600600600   
Total equity:101,034103,426132,78333,67124,37927,866
TOTAL LIABILITIES AND EQUITY:111,705113,999142,42943,77428,98631,051

Income Statement (P&L) ($ in thousands)

9/30/2023
12/31/2022
TTM
9/30/2022
9/30/2021
9/30/2020
9/30/2019
9/30/2018
Revenues  909011090818
Other operating income      818
Other income   60110  
Cost of revenue
(Cost of Goods and Services Sold)
      (75)
Gross profit:  909011090743
Operating expenses(31,307)(33,316)(23,532)(17,711)(15,598)(13,789)
Other undisclosed operating loss  (90)(90)(110)(90)(743)
Operating loss:(31,307)(33,316)(23,532)(17,711)(15,598)(13,789)
Nonoperating income432251477163361,253
Investment income, nonoperating4322512626853 
Debt instrument, convertible, beneficial conversion feature      1,595
Other nonoperating income      
Interest and debt expense 3,586 322(16)(16)450
Loss from continuing operations before equity method investments, income taxes:(27,289)(33,065)(22,732)(17,564)(15,579)(12,087)
Other undisclosed income (loss) from continuing operations before income taxes    1631,141(450)
Income (loss) from continuing operations before income taxes:(27,289)(33,065)(22,732)(17,548)15,562(12,537)
Income tax expense(144)(576)(1)   
Other undisclosed loss from continuing operations (576)     
Income (loss) from continuing operations:(28,009)(33,641)(22,733)(17,548)15,562(12,537)
Income (loss) before gain (loss) on sale of properties:(24,415)(33,641)(22,733)(17,548)15,562(12,537)
Income from discontinued operations 3,586     
Other undisclosed net loss (3,586) (321) (31,124) 
Net loss attributable to parent:(28,009)(33,641)(23,054)(17,548)(15,562)(12,537)
Preferred stock dividends and other adjustments   (1,451)   
Other undisclosed net loss available to common stockholders, basic      
Net loss available to common stockholders, diluted:(28,009)(33,641)(24,505)(17,548)(15,562)(12,537)

Comprehensive Income ($ in thousands)

9/30/2023
12/31/2022
TTM
9/30/2022
9/30/2021
9/30/2020
9/30/2019
9/30/2018
Net loss:(28,009)(33,641)(23,054)(17,548)(15,562)(12,537)
Comprehensive loss, net of tax, attributable to parent:(28,009)(33,641)(23,054)(17,548)(15,562)(12,537)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: